Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

Aim: Long-term survivors (LTS) after glioma recurrence while on bevacizumab (Bev) therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & metho...

Полное описание

Библиографические подробности
Главные авторы:	Liang Yen Liu, Matthew S Ji, Nhung T Nguyen, Frances E Chow, Donna M Molaie, Sean T Pianka, Richard M Green, Linda M Liau, Benjamin M Ellingson, Phioanh L Nghiemphu, Timothy F Cloughesy, Albert Lai
Формат:	Статья
Язык:	English
Опубликовано:	Taylor & Francis Group 2019-06-01
Серии:	CNS Oncology
Предметы:	bevacizumab glioblastoma glioma long term progression recurrence
Online-ссылка:	https://www.futuremedicine.com/doi/10.2217/cns-2019-0007

Схожие документы

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab
по: Alissa Thomas, и др.
Опубликовано: (2018-01-01)

A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab
по: Josie Hayes, и др.
Опубликовано: (2016-10-01)

A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
по: Patrick Roth, и др.
Опубликовано: (2020-06-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
по: Bai X, и др.
Опубликовано: (2024-11-01)

Bevacizumab in recurrent WHO grades II–III glioma
по: Soufyan Annakib, и др.
Опубликовано: (2023-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
по: Joan Manel Gasent Blesa, и др.
Опубликовано: (2012-12-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
по: D. R. Naskhletashvili, и др.
Опубликовано: (2015-04-01)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
по: Mesti Tanja, и др.
Опубликовано: (2015-03-01)

Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
по: Moire Cuncannon, и др.
Опубликовано: (2019-05-01)

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials
по: SiYao Wei, и др.
Опубликовано: (2024-07-01)

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab
по: Tomohiro Hosoya, и др.
Опубликовано: (2024-11-01)

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells
по: Mesti Tanja, и др.
Опубликовано: (2018-11-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
по: N. García-Romero, и др.
Опубликовано: (2020-06-01)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
по: Masahiro Nishikawa, и др.
Опубликовано: (2021-03-01)

Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis
по: Zhaoyan Chen, и др.
Опубликовано: (2024-05-01)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
по: Kathleen Van Dyk, и др.
Опубликовано: (2022-06-01)

Opportunities and Challenges for Successful Use of Bevacizumab in Pediatrics
по: Amy eBarone, и др.
Опубликовано: (2013-04-01)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
по: Hiroyuki Tatekawa, и др.
Опубликовано: (2021-03-01)

Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma
по: Rebecca Kassubek, и др.
Опубликовано: (2023-05-01)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
по: Celina Bihan, и др.
Опубликовано: (2012-09-01)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
по: Eudocia Q. Lee, и др.
Опубликовано: (2019-10-01)

Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center
по: Margarida Simão-Rafael, и др.
Опубликовано: (2023-12-01)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
по: Pia Banerjee, и др.
Опубликовано: (2015-01-01)

Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
по: Ramon F. Barajas, и др.
Опубликовано: (2016-10-01)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
по: George Ansstas, и др.
Опубликовано: (2016-01-01)

Differential expression of the circadian clock network correlates with tumour progression in gliomas
по: Marina Petkovic, и др.
Опубликовано: (2023-07-01)

Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
по: Barbara Castelli, и др.
Опубликовано: (2023-09-01)

The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
по: Giovanni Luca Gravina, и др.
Опубликовано: (2017-01-01)

Survival prediction using apparent diffusion coefficient values in recurrent glioblastoma under bevacizumab treatment: an updated systematic review and meta-analysis
по: Dong Liu, и др.
Опубликовано: (2024-07-01)

Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report
по: Barbara Castelli, и др.
Опубликовано: (2024-02-01)

Machine-Learning-Based Radiomics MRI Model for Survival Prediction of Recurrent Glioblastomas Treated with Bevacizumab
по: Samy Ammari, и др.
Опубликовано: (2021-07-01)

Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review
по: Oguz Ozel, и др.
Опубликовано: (2016-08-01)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
по: Emil Lou, и др.
Опубликовано: (2013-04-01)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
по: Seung Won Choi, и др.
Опубликовано: (2018-05-01)

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
по: Minjie Fu, и др.
Опубликовано: (2023-06-01)

Circadian Alterations in a Murine Model of Hypothalamic Glioma
по: José M. Duhart, и др.
Опубликовано: (2017-10-01)

Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines
по: Valerie J. Marallano, и др.
Опубликовано: (2024-03-01)

Selected cytostatic drugs in the treatment of brain glioma – literature review
по: Jarosław Bała, и др.
Опубликовано: (2021-11-01)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
по: Lei She, и др.
Опубликовано: (2022-08-01)

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy
по: Shanmu Jin, и др.
Опубликовано: (2024-03-01)